<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>Anthropic's latest biotech buy is a one-man stealth startup run by a pseudonymous Twitter poster — Live Feed</title><link>https://www.live-feeds.com/feed/anthropic-s-latest-biotech-buy-is-a-one-man-stealth-startup-run-by-a-pseudonymous-twitter-poster</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/anthropic-s-latest-biotech-buy-is-a-one-man-stealth-startup-run-by-a-pseudonymous-twitter-poster/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>Anthropic Buys One-Person Biotech Mithril Medicine</title><link>https://www.live-feeds.com/feed/anthropic-s-latest-biotech-buy-is-a-one-man-stealth-startup-run-by-a-pseudonymous-twitter-poster</link><guid isPermaLink="false">https://www.live-feeds.com/feed/anthropic-s-latest-biotech-buy-is-a-one-man-stealth-startup-run-by-a-pseudonymous-twitter-poster#u165030</guid><pubDate>Sat, 31 Oct 2026 07:30:14 +0000</pubDate><description>Artificial intelligence developer Anthropic has acquired Mithril Medicine, a stealth startup operated by a single pseudonymous developer who used the Claude AI model to coordinate multiple laboratories and pursue treatments for rare muscular dystrophies. The July transaction provides Anthropic with internal rare-disease drug programs and expands its footprint in the life sciences sector. Alongside the startup purchase, Anthropic disclosed collaborations with several external life sciences partners utilizing its AI technology for tasks including antibody design and clinical trial planning.Why i</description></item>
</channel></rss>